GX SCIENCES
Innovative Genomic Solutions

Gene Comprehensive Nutrigenomic Report

Accession Number: ##########
Report Generated: August 21, 2018
Specimen Received: ##/##/####
Created For: ###### ######
DOB: ##/##/####
Male

Do not make any decisions about your health solely based on the information contained in this report. Always consult with a licensed and experienced health practitioner when you receive this report.

GX Sciences | 844-258-5564 | www.GXSciences.com
Lab | 4150 Freidrich Lane, Ste H | Austin, TX 78744
Laboratory Director: James W. Jacobson, Ph.D

– 10 – Male

(-/-) No clinical abnormality | (+/-) Heterozygous result | (+/+) Homozygous result

rsID	Gene	Genetic Result	Therapeutics Associated With Positive Result	Highly Recommended Therapeutics / Neurobiologix Formulas	Provider Discretion: As Needed Formula Recommendations	Lifestyle Recommendations	Laboratory Recommendations
Gastrointestinal							
Inflammation Environmental							
rs10156191	AOC1	+/-	Poor Ability To Break Down External Histamine		GI Hist Support™	Avoid Foods Containing Histamine	
rs11558538	HNMT	-/-					
rs12995000	HNMT	-/-					
rs492602	FUT2	+/+	Probiotics Needed	**Biotic Blend Pro™, Biotic Multi Blend Pro™, Probiotic Boost Daily™, Biotic Boost Chews For Kids™**			Consider Microbiome Testing If GI Inflammation Present
rs2248814	NOS2	+/-	Anti-Infectives, Beta Glucans		Neuro-Immune Infection Control™		
rs2187668	HLA DQA1	-/-	High Risk of Gluten Based Issues				
rs2858331	HLA DQA2	+/-					
Lactose Intolerance							
rs4988235	MCM6	+/+	High incidence of lactose Intolerance			Avoid Lactose (milk products)	
Autophagy Consideration							
rs510432	ATG5	+/-	Curcumin, Lithium Orotate, D-Chiro-Inositol, Catechins, Resveratrol, Caffeine, 12 Hour Fasting	**N.A.S. Enhancer™ (NRF2|Autophagy|SOD Support), Metabolic Stimulator™**		Calorie Restriction, 12-15 Hour Fasting	Routine Blood Sugar, Insulin and Hb A1c
rs10210302	ATG16L1	+/-					
rs2066845	NOD2 CARD15	-/-	Increase susceptibility to bacterial GI infections and Crohn's		Neuro-Immune Infection ControlTM , N.A.S. EnhancerTM (NRF2|Autophagy|SOD Support)		
rs2241880	ATG16L1	+/-					

Summary for Gastrointestinal

Highly Recommended Therapeutics / Neurobiologix Formulas

- **Biotic Blend Pro™, Biotic Multi Blend Pro™, Probiotic Boost Daily™, Biotic Boost Chews For Kids™**
- **N.A.S. Enhancer™ (NRF2|Autophagy|SOD Support), Metabolic Stimulator™**

Lifestyle Recommendations

- Avoid Foods Containing Histamine
- Avoid Lactose (milk products)
- Calorie Restriction, 12-15 Hour Fasting

Laboratory Recommendations

- Consider Microbiome Testing If GI Inflammation Present
- Routine Blood Sugar, Insulin and Hb A1c

Gene Information Key

rsID	Gene	"-" variant	"+" variant
rs10156191	AOC1	C	T
rs10210302	ATG16L1	C	T
rs11558538	HNMT	C	T
rs12995000	HNMT	C	T
rs2066845	NOD2/CARD15	G	C
rs2187668	HLA-DQA1	C	T
rs2241880	ATG16L1	A	G
rs2241880	ATG16L1	A	G
rs2248814	NOS2	G	A
rs2858331	HLA-DQA2	A	G
rs492602	FUT2	A	G
rs4988235	MCM6	G	A
rs510432	ATG5	C	T

Definitions

GASTROINTESTINAL	
MCM6	A mutation in a DNA control region located in the MCM6 gene is associated with expression of the lactase gene. Individuals homozygous for this polymorphism are more likely to have hypolactasia, or lactose intolerance.
INFLAMMATORY	This enzyme category has significant effects on the inflammatory state of a person's body. Polymorphisms in these specific enzymes will significantly increase the levels of inflammation in the body. By supplementing these enzyme deficiencies, the patient will effectively reduce inflammatory damage to the body.
AOC1	The SNP rs10156191 encodes a weaker form of the histamine degradation enzyme Amine Oxidase, Copper Containing 1 (AOC1). This mutation, Thr16Met, is predicted to produce an enzyme with less catalytic activity and associated higher levels of pro-inflammatory amines like histamine and putrescine.
ATG16L1	The ATG16L1 gene encodes a protein that is a vital component of a protein complex necessary for the cellular phenomena known as autophagy. Autophagy is the process of degrading and cleaning of inert debris of the cell. Weakness in autophagy leads to abnormal accumulation of cellular “garbage” that will eventually affect the cellular function and lead to autophagy related disease states in including many neurological and immunological diseases, DM Type 2 and fatty liver disease.
ATG5	Autophagy-related 5 protein (ATG5) is an important intracellular mediator of the autophagy response. ATG5 is involved in a wide range of "quality control" features inside the cell: autophagy vesicle formation, innate immune system signaling, consumption of damaged mitochondria, and apoptosis. Mutations in the ATG5 gene are associated with numerous neurological, immunological and endocrine syndromes.
FUT2	Fucosyltransferase 2 (FUT2) is responsible for producing specific sugar groups that are secreted by the intestinal cells into the bowel to attract "good bacteria" . Polymorphisms in this gene produce "poor secreter" status. Lack of these sugars allows for gut dysbiosis and a higher risk of inflammatory bowel disease.
HLA-DQA1	Major histocompatibility complex, DQ alpha 1 (HLA-DQA1) is a human gene responsible for a cell surface receptor essential to the function of the immune system. Patients with a polymorphism in this gene are at higher risk for auto-immune based inflammatory disease including Celiac disease, Crohn's, Ulcerative Colitis, and gluten sensitivity.
HLA-DQA2	Major histocompatibility complex, DQ alpha 2 (HLA-DQA2) is a human gene responsible for a cell surface receptor essential to the function of the immune system. Patients with a polymorphism in this gene are at higher risk for auto-immune based inflammatory disease including Celiac disease, Crohn's, Ulcerative Colitis, and gluten sensitivity.
HNMT	The HNMT gene encodes the histamine degradative enzyme, histamine N-methyltransferase. HNMT, in contrast to AOC1, requires the methyl donor S-adenosylmethionine and a complete methylation pathway for normal function. Polymorphisms in HNMT gene expression or protein coding are predicted to prolong the pro-inflammatory effects of histamine signaling.
HNMT:Thr105Ile	The HNMT gene encodes the histamine degradative enzyme, histamine N-methyltransferase. HNMT, in contrast to AOC1, requires the methyl donor S-adenosylmethionine and a complete methylation pathway for normal function. Polymorphisms in HNMT gene expression or protein coding are predicted to prolong the pro-inflammatory effects of histamine signaling.
NOD2/CARD15	NOD2 is a protein that integrates extracellular sensing of bacterial cell wall components with intracellular pro-inflammatory signaling to the nucleus. Mutations in the NOD2 gene are associated with poor ability to recognize abnormal bacterial pathogens in the intestinal tract and increased risk of intestinal dysbiosis.
NOS2	Nitric Oxide Synthanse 2 (NOS2) is responsible for producing nitric oxide, a biologic mediator used by the nervous system, immune system and in blood vessel function. Polymorphisms in this enzyme can cause reduced immune system function, exercise intolerance and fatigue.

Disclaimers

METHODOLOGY AND LIMITATIONS:

Testing for genetic variation/mutation on listed genes was performed using ProFlex PCR and Real-Time PCR with TaqMan® allele-specific probes on the QuantStudio 12K Flex. All genetic testing is performed by GX Sciences, 4150 Freidrich Lane, Ste H, Austin, TX. 78744. This test will not detect all the known alleles that result in altered or inactive tested genes. This test does not account for all individual variations in the individual tested. Test results do not rule out the possibility that this individual could be a carrier of other mutations/variations not detected by this gene mutation/variation panel. Rare mutations surrounding these alleles may also affect our detection of genetic variations. Thus, the interpretation is given as a probability. Therefore, this genetic information shall be interpreted in conjunction with other clinical findings and familial history for the administration of specific nutrients. Patients should receive appropriate genetic counseling to explain the implications of these test results. Details of assay performance and algorithms leading to clinical recommendations are available upon request. The analytical and performance characteristics of this laboratory developed test (LDT) were determined by GX Sciences' laboratory pursuant to Clinical Laboratory Improvement Amendments (CLIA) requirements.
CLIA #: 45D2144988

DISCLAIMER:

This test was developed and its performance characteristics determined by GX Sciences. It has not been cleared or approved by the FDA. The laboratory is regulated under CLIA and qualified to perform high-complexity testing. This test is used for clinical purposes. It should not be regarded as investigational or for research. rsIDs for the alleles being tested were obtained from the dbSNP database (Build 142).

DISCLAIMER:

UND Result: If you have received the result Variant undetermined (UND) this indicates that we were not able to determine your carrier status based on your raw data. Please refer to the GX Sciences genetic knowledge database for more information: https://www.gxsciences.com/kb_results.asp

DISCLAIMER:

Report contents and report recommendations are created and approved by GX Sciences. Sole responsibility for the proper use of the information on the GX Sciences report rests with the user, or those professionals with whom the user may consult. Nutrigenomic Testing and Neurobiologix Dietary Supplements are not "Designated Health Services" covered by Medicare or Medicaid and may not be reimbursed under any state or Federal health care program.

DISCLAIMER:

These products are not approved by the Food and Drug Administration and are not intended to diagnose, treat, cure or prevent a disease. These recommendations are for report purposes only and an individual is not required to use such products. These are recommendations only and do not replace the advisement of your own healthcare practitioner.

GX Sciences SNP References

GASTROINTESTINAL SNP References

MCM6

• Bersaglieri, T., Sabeti, P. C., Patterson, N., Vanderploeg, T., Schaffner, S. F., Drake, J. A., … Hirschhorn, J. N. (2004). Genetic Signatures of Strong Recent Positive Selection at the Lactase Gene. The American Journal of Human Genetics, 74(6), 1111–1120. https://doi.org/10.1086/421051 • Bersaglieri, T., Sabeti, P. C., Patterson, N., Vanderploeg, T., Schaffner, S. F., Drake, J. A., … Hirschhorn, J. N. (2004). Genetic Signatures of Strong Recent Positive Selection at the Lactase Gene. The American Journal of Human Genetics, 74(6), 1111–1120. https://doi.org/10.1086/421051 • Enattah, N. S., Sahi, T., Savilahti, E., Terwilliger, J. D., Peltonen, L., & Järvelä, I. (2002). Identification of a variant associated with adult-type hypolactasia. Nature Genetics, 30(2), 233–237. https://doi.org/10.1038/ng826

INFLAMMATORY SNP References

AOC1

• McGrath, A. P., Hilmer, K. M., Collyer, C. A., Shepard, E. M., Elmore, B. O., Brown, D. E., … Guss, J. M. (2009). Structure and inhibition of human diamine oxidase. Biochemistry, 48(41), 9810–9822. https://doi.org/10.1021/bi9014192 • McGrath, A. P., Hilmer, K. M., Collyer, C. A., Shepard, E. M., Elmore, B. O., Brown, D. E., … Guss, J. M. (2009). Structure and Inhibition of Human Diamine Oxidase - Biochemistry (ACS Publications). Biochemistry, 48(41), 9810–9822. https://doi.org/10.1021/bi9014192 • Solismaa, A., Kampman, O., Lyytikäinen, L. P., Seppälä, N., Viikki, M., Mononen, N., … Leinonen, E. (2017). Histaminergic gene polymorphisms associated with sedation in clozapine-treated patients. European Neuropsychopharmacology, 27(5), 442–449. https://doi.org/10.1016/j.euroneuro.2017.03.009 • Schwelberger, H. G. (2007). The origin of mammalian plasma amine oxidases. In Journal of Neural Transmission (Vol. 114, pp. 757–762). https://doi.org/10.1007/s00702-007-0684-x

ATG16L1

• Role of autophagy genetic variants for the risk of Candida infections Diana C. Rosentul, Theo S. Plantinga, Marius Farcas, Marije Oosting, Omar J.M. Hamza, William K. Scott, Barbara D. Alexander, John C. Yang, Gregory M. Laird, Leo A.B. Joosten, Jos W. M. van der Meer, John R. Perfect, Bart-Jan Kullberg, Andre J.A.M. van der Ven, Melissa D. Johnson, Mihai G. Netea Med Mycol. 2014 May; 52(4): 333–341. Published online 2014 Apr 8.doi: 10.1093/mmy/myt035 • The T300A Crohn's disease risk polymorphism impairs function of the WD40 domain of ATG16L1 Emilio Boada-Romero, Inmaculada Serramito-Gómez, María P. Sacristán, David L. Boone, Ramnik J. Xavier, Felipe X. Pimentel-Muiños Nat Commun. 2016; 7: 11821. Published online 2016 Jun 8. doi: 10.1038/ncomms11821 • Atg16L1 T300A variant decreases selective autophagy resulting in altered cytokine signaling and decreased antibacterial defense Kara G. Lassen, Petric Kuballa, Kara L. Conway, Khushbu K. Patel, Christine E. Becker, Joanna M. Peloquin, Eduardo J. Villablanca, Jason M. Norman, Ta-Chiang Liu, Robert J. Heath, Morgan L. Becker, Lola Fagbami, Heiko Horn, Johnathan Mercer, Omer H. Yilmaz, Jacob D. Jaffe, Alykhan F. Shamji, Atul K. Bhan, Steven A. Carr, Mark J. Daly, Herbert W. Virgin, Stuart L. Schreiber, Thaddeus S. Stappenbeck, Ramnik J. Xavier Proc Natl Acad Sci U S A. 2014 May 27; 111(21): 7741–7746. Published online 2014 May 12. doi: 10.1073/pnas.1407001111 • The autophagy gene Atg16l1 differentially regulates Treg and TH2 cells to control intestinal inflammation Agnieszka M Kabat, Oliver J Harrison, Thomas Riffelmacher, Amin E Moghaddam, Claire F Pearson, Adam Laing, Lucie Abeler-Dörner, Simon P Forman, Richard K Grencis, Quentin Sattentau, Anna Katharina Simon, Johanna Pott, Kevin J Maloy eLife. 2016; 5: e12444. Published online 2016 Feb 24. doi: 10.7554/eLife.12444 • T300A polymorphism of ATG16L1 and susceptibility to inflammatory bowel diseases: A meta-analysis Jia-Fei Cheng, Yue-Ji Ning, Wei Zhang, Zong-Hai Lu, Lin Lin World J Gastroenterol. 2010 Mar 14; 16(10): 1258–1266. Published online 2010 Mar 14. doi: 10.3748/wjg.v16.i10.1258 • ATG16L1: A multifunctional susceptibility factor in Crohn disease Mohammad Salem, Mette Ammitzboell, Kris Nys, Jakob Benedict Seidelin, Ole Haagen Nielsen Autophagy. 2015 Apr; 11(4): 585–594. Published online 2015 Apr 23. doi: 10.1080/15548627.2015.1017187 • The Crohn's disease: associated ATG16L1 variant and Salmonella invasion Jeannette S Messer, Stephen F Murphy, Mark F Logsdon, James P Lodolce, Wesley A Grimm, Sarah J Bartulis, Tiphanie P Vogel, Melisa Burn, David L Boone BMJ Open. 2013; 3(6): e002790. Published online 2013 Jun 4. doi: 10.1136/bmjopen-2013-002790 • NOD2 and ATG16L1 polymorphisms affect monocyte responses in Crohn's disease Dylan M Glubb, Richard B Gearry, Murray L Barclay, Rebecca L Roberts, John Pearson, Jacqui I Keenan, Judy McKenzie, Robert W Bentley World J Gastroenterol. 2011 Jun 21; 17(23): 2829–2837. Published online 2011 Jun 21. doi: 10.3748/wjg.v17.i23.2829 • Integrated Genomics of Crohn's Disease Risk Variant Identifies a Role for CLEC12A in Antibacterial Autophagy Jakob Begun, Kara G. Lassen, Humberto B. Jijon, Leigh A. Baxt, Gautam Goel, Robert J. Heath, Aylwin Ng, Jenny M. Tam, Szu-Yu Kuo, Eduardo J. Villablanca, Lola Fagbami, Marije Oosting, Vinod Kumar, Monica Schenone, Steven A. Carr, Leo A.B. Joosten, Jatin M. Vyas, Mark J. Daly, Mihai G. Netea, Gordon D. Brown, Cisca Wijmenga, Ramnik J. Xavier Cell Rep. 2015 Jun 30; 11(12): 1905–1918. Published online 2015 Jun 18. doi: 10.1016/j.celrep.2015.05.045 • Polymorphisms in Autophagy Genes Are Associated with Paget Disease of Bone Ricardo Usategui-Martín, Judith García-Aparicio, Luis Corral-Gudino, Ismael Calero-Paniagua, Javier Del Pino-Montes, Rogelio González Sarmiento PLoS One. 2015; 10(6): e0128984. Published online 2015 Jun 1. doi: 10.1371/journal.pone.0128984 • Impact of T300A Variant of ATG16L1 on Antibacterial Response, Risk of Culture Positive Infections, and Clinical Course of Crohn's Disease Mohammad Salem, Ole Haagen Nielsen, Kris Nys, Shiva Yazdanyar, Jakob Benedict Seidelin Clin Transl Gastroenterol. 2015 Nov; 6(11): e122. Published online 2015 Nov 5. doi: 10.1038/ctg.2015.47 • NOD2/CARD15, ATG16L1 and IL23R gene polymorphisms and childhood-onset of Crohn's disease Maria Gazouli, Ioanna Pachoula, Ioanna Panayotou, Gerassimos Mantzaris, George Chrousos, Nicholas P Anagnou, Eleftheria Roma-Giannikou World J Gastroenterol. 2010 Apr 14; 16(14): 1753–1758. Published online 2010 Apr 14. doi: 10.3748/wjg.v16.i14.1753 • Impaired Autophagy of an Intracellular Pathogen Induced by a Crohn's Disease Associated ATG16L1 Variant Petric Kuballa, Alan Huett, John D. Rioux, Mark J. Daly, Ramnik J. Xavier PLoS ONE. 2008; 3(10): e3391. Published online 2008 Oct 13. doi: 10.1371/journal.pone.0003391 • Crohn disease ATG16L1 polymorphism increases susceptibility to infection with Helicobacter pylori in humans Deepa Raju, Séamus Hussey, Nicola L. Jones Autophagy. 2012 Sep 1; 8(9): 1387–1388. doi: 10.4161/auto.21007 • Crohn disease: A current perspective on genetics, autophagy and immunity Thaddeus S. Stappenbeck, John D. Rioux, Atsushi Mizoguchi, Tatsuya Saitoh, Alan Huett, Arlette Darfeuille-Michaud, Tom Wileman, Noboru Mizushima, Simon Carding, Shizuo Akira, Miles Parkes, Ramnik J. Xavier Autophagy. 2011 Apr 1; 7(4): 355–374. doi: 10.4161/auto.7.4.13074 • Interaction of the major inflammatory bowel disease susceptibility alleles in Crohn's disease patients Veronika Csöngei, Luca Járomi, Enik? Sáfrány, Csilla Sipeky, Lili Magyari, Bernadett Faragó, Judit Bene, Noémi Polgár, Lilla Lakner, Patrícia Sarlós, Márta Varga, Béla Melegh World J Gastroenterol. 2010 Jan 14; 16(2): 176–183. Published online 2010 Jan 14. doi: 10.3748/wjg.v16.i2.176

ATG5

• Anton, Raymond F et al. 2008. “Pharmacogenomics” ed. Yoshiaki Tsuji. Nature Genetics 16(1): 268–78. http://www.ncbi.nlm.nih.gov/pubmed/26671228 (May 14, 2018). • White, Kirsten A M et al. 2016. “Variants in Autophagy-Related Genes and Clinical Characteristics in Melanoma: A Population-Based Study.” Cancer Medicine 5(11): 3336–45. http://www.ncbi.nlm.nih.gov/pubmed/27748080. • Martin, Lisa J et al. 2012. “Functional Variant in the Autophagy-Related 5 Gene Promotor Is Associated with Childhood Asthma” ed. Dominik Hartl. PLoS ONE 7(4): e33454. http://dx.plos.org/10.1371/journal.pone.0033454. • Yuan, Jiali et al. 2017. “Polymorphisms in Autophagy Related Genes and the Coal Workers’ Pneumoconiosis in a Chinese Population.” Gene 632: 36–42. http://www.ncbi.nlm.nih.gov/pubmed/28844669.

FUT2

• Kimura K; Wakamatsu A; Suzuki Y; et al. (2006). "Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes". Genome Res. 16 (1): 55–65. PMID 16344560. • Reguigne-Arnould I; Couillin P; Mollicone R; et al. (1995). "Relative positions of two clusters of human alpha-L-fucosyltransferases in 19q (FUT1-FUT2) and 19p (FUT6-FUT3-FUT5) within the microsatellite genetic map of chromosome 19". Cytogenet. Cell Genet. 71 (2): 158–62. doi:10.1159/000134098. PMID 7656588. • Ball SP, Tongue N, Gibaud A, Le Pendu J, Mollicone R, Gerard G, Oriol R (Feb 1992). "The human chromosome 19 linkage group FUT1 (H), FUT2 (SE), LE, LU, PEPD, C3, APOC2, D19S7 and D19S9". Ann Hum Genet 55 (Pt 3): 225–33. PMID 1763885. • "Entrez Gene: FUT2 fucosyltransferase 2 (secretor status included)". • Koda Y, Soejima M, Wang B, Kimura H (1997). "Structure and expression of the gene encoding secretor-type galactoside 2-alpha-L-fucosyltransferase (FUT2)". Eur. J. Biochem. 246 (3): 750–5. • Strausberg RL; Feingold EA; Grouse LH; et al. (2003). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences". Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903.PMID 12477932.

HLA-DQA1

• Schiffenbauer J, Didier DK, Klearman M, et al. (1987). "Complete sequence of the HLA DQ alpha and DQ beta cDNA from a DR5/DQw3 cell line". J. Immunol. 139 (1): 228–33. PMID 3584986. • Kao HT, Gregersen PK, Tang JC, et al. (1989). "Molecular analysis of the HLA class II genes in two DRw6-related haplotypes, DRw13 DQw1 and DRw14 DQw3.". J. Immunol. 142 (5): 1743–7. PMID 2493052. • Jonsson AK, Hyldig-Nielsen JJ, Servenius B, et al. (1987). "Class II genes of the human major histocompatibility complex. Comparisons of the DQ and DX alpha and beta genes". J. Biol. Chem. 262 (18): 8767–77. PMID 3036828. • Schmidt H, Williamson D, Ashley-Koch A (2007). "HLA-DR15 haplotype and multiple sclerosis: a HuGE review.". Am. J. Epidemiol. 165 (10): 1097–109. doi:10.1093/aje/kwk118. PMID 17329717. • Marsh SG, Bodmer JG (1993). "HLA class II nucleotide sequences, 1992.". Tissue Antigens 40 (5): 229–43. PMID 1362295. • Todd JA, Fukui Y, Kitagawa T, Sasazuki T (1990). "The A3 allele of the HLA-DQA1 locus is associated with susceptibility to type 1 diabetes in Japanese.". Proc. Natl. Acad. Sci. U.S.A. 87 (3): 1094–8. . PMID 2300572. • Liu CP, Bach FH, Wu SK (1988). "Molecular studies of a rare DR2/LD-5a/DQw3 HLA class II haplotype. Multiple genetic mechanisms in the generation of polymorphic HLA class II genes". J. Immunol. 140 (10): 3631–9. PMID 3129499. • Horn GT, Bugawan TL, Long CM, et al. (1988). "Sequence analysis of HLA class II genes from insulin-dependent diabetic individuals". Hum. Immunol. 21 (4): 249–63. PMID 3372263.

HLA-DQA2

• A family study confirms that the HLA-DP associations with celiac disease are the result of an extended HLA-DR3 haplotype. Bolsover, W.J., Hall, M.A., Vaughan, R.W., Welsh, K.I., Ciclitira, P.J. Hum. Immunol. (1991) • Entrez Gene: HLA-DQA2 major histocompatibility complex, class II, DQ alpha 2" • HLA class II-associated genetic susceptibility in multiple sclerosis: a critical evaluation. Olerup, O., Hillert, J. Tissue Antigens (1991) • The cryptic HLA-DQA2 ("DX alpha") gene is expressed in human B cell lines. Yu, L.P., Sheehy, M.J. J. Immunol. (1991) • HLA-DQA and DQB alleles contribute to susceptibility to insulin-dependent diabetes mellitus. Wang, H., He, R. Chin. Med. Sci. J. (1993) • Evidence for a primary association of celiac disease to a particular HLA-DQ alpha/beta heterodimer. Sollid, L.M., Markussen, G., Ek, J., Gjerde, H., Vartdal, F., Thorsby, E. J. Exp. Med. (1989) • Polymorphic DQ alpha and DQ beta interactions dictate HLA class II determinants of allo-recognition. Kwok,

W.W., Mickelson, E., Masewicz, S., Milner, E.C., Hansen, J., Nepom, G.T. J. Exp. Med. (1990) • Celiac disease is associated with an extended HLA-DR3 haplotype which includes HLA-DPw1. Hall, M.A., Lanchbury, J.S., Bolsover, W.J., Welsh, K.I., Ciclitira, P.J. Hum. Immunol. (1990) • Trans-encoded DQ alpha beta heterodimers confer susceptibility to myasthenia gravis disease. Khalil, I., Berrih-Aknin, S., Lepage, V., Loste, M.N., Gajdos, P., Hors, J., Charron, D., Degos, L. C. R. Acad. Sci. III, Sci. Vie (1993) • A combination of HLA-DQ beta Asp57-negative and HLA DQ alpha Arg52 confers susceptibility to insulin-dependent diabetes mellitus. Khalil, I., d'Auriol, L., Gobet, M., Morin, L., Lepage, V., Deschamps, I., Park, M.S., Degos, L., Galibert, F., Hors, J. J. Clin. Invest. (1990)

HNMT

• Keeling, Brett H et al. 2010. “Histamine N-Methyltransferase Thr105Ile Is Not Associated with Parkinson’s Disease or Essential Tremor.” Parkinsonism & Related Disorders 16(2): 112–14. http://www.ncbi.nlm.nih.gov/pubmed/19773194. • Anton, Raymond F et al. 2008. “Pharmacogenomics” ed. Yoshiaki Tsuji. Nature Genetics 16(1): 268–78. http://www.ncbi.nlm.nih.gov/pubmed/26671228 (May 14, 2018). • “Rs12995000 (SNP) - Explore This Variant - Homo Sapiens - Ensembl Genome Browser 92.” https://useast.ensembl.org/Homo_sapiens/Variation/Explore?r=2:137963579-137964579;v=rs12995000;vdb=variation;vf=8000533 (May 14, 2018).

NOD2

• Anton, Raymond F et al. 2008. “Pharmacogenomics” ed. Yoshiaki Tsuji. Nature Genetics 16(1): 268–78. http://www.ncbi.nlm.nih.gov/pubmed/26671228 (May 14, 2018). • Ogura, Yasunori et al. 2001. “A Frameshift Mutation in NOD2 Associated with Susceptibility to Crohn’s Disease.” Nature 411(6837): 603–6. http://www.ncbi.nlm.nih.gov/pubmed/11385577. • Nuij, V. J.A.A., M. P. Peppelenbosch, C. J. Woude, and G. M. Fuhler. 2017. “Genetic Polymorphism in ATG16L1 Gene Is Associated with Adalimumab Use in Inflammatory Bowel Disease.” Journal of Translational Medicine 15(1). • Hugot, Jean-Pierre et al. 2001. “Association of NOD2 Leucine-Rich Repeat Variants with Susceptibility to Crohn’s Disease.” Nature 411(6837): 599–603. http://www.ncbi.nlm.nih.gov/pubmed/11385576.

NOS2

• Genetic variation in immunoregulatory pathways and atopic phenotypes in infancy. Hoffjan, S., Ostrovnaja, I., Nicolae, D., Newman, D.L., Nicolae, R., Gangnon, R., Steiner, L., Walker, K., Reynolds, R., Greene, D., Mirel, D., Gern, J.E., Lemanske, R.F., Ober, C. J. Allergy Clin. Immunol. (2004) [Pubmed] • Cross-talk between cyclooxygenase and nitric oxide pathways: prostaglandin E2 negatively modulates induction of nitric oxide synthase by interleukin 1. Tetsuka, T., Daphna-Iken, D., Srivastava, S.K., Baier, L.D., DuMaine, J., Morrison, A.R. Proc. Natl. Acad. Sci. U.S.A. (1994) [Pubmed] • Molecular cloning and expression of inducible nitric oxide synthase from human hepatocytes. Geller, D.A., Lowenstein, C.J., Shapiro, R.A., Nussler, A.K., Di Silvio, M., Wang, S.C., Nakayama, D.K., Simmons, R.L., Snyder, S.H., Billiar, T.R. Proc. Natl. Acad. Sci. U.S.A. (1993) [Pubmed] • Role of interferon regulatory factor 1 in induction of nitric oxide synthase. Martin, E., Nathan, C., Xie, Q.W. J. Exp. Med. (1994) [Pubmed] • Physiology and pathophysiology of nitric oxide. Ignarro, L.J. Kidney Int. Suppl. (1996) [Pubmed] • Regulation of the mammalian heart function by nitric oxide. Massion, P.B., Pelat, M., Belge, C., Balligand, J.L. Comp. Biochem. Physiol., Part A Mol. Integr. Physiol. (2005) [Pubmed] • Association of elevated glial expression of interleukin-1beta with improved survival in patients with glioblastomas multiforme. Cuny, E., Loiseau, H., Penchet, G., Ellie, E., Arsaut, J., Vital, A., Vincendeau, P., Demotes-Mainard, J. J. Neurosurg. (2002) [Pubmed] • Platelet phagocytosis and processing of beta-amyloid precursor protein as a mechanism of macrophage activation in atherosclerosis. De Meyer, G.R., De Cleen, D.M., Cooper, S., Knaapen, M.W., Jans, D.M., Martinet, W., Herman, A.G., Bult, H., Kockx, M.M. Circ. Res. (2002) [Pubmed] • Modulation of prostaglandin biosynthesis by nitric oxide and nitric oxide donors. Mollace, V., Muscoli, C., Masini, E., Cuzzocrea, S., Salvemini, D. Pharmacol. Rev. (2005) [Pubmed] • Expression of type II nitric oxide synthase in primary human astrocytes and microglia: role of IL-1beta and IL-1 receptor antagonist. Liu, J., Zhao, M.L., Brosnan, C.F., Lee, S.C. J. Immunol. (1996) [Pubmed] • Linkage and association with the NOS2A locus on chromosome 17q11 in multiple sclerosis. Barcellos, L.F., Begovich, A.B., Reynolds, R.L., Caillier, S.J., Brassat, D., Schmidt, S., Grams, S.E., Walker, K., Steiner, L.L., Cree, B.A., Stillman, A., Lincoln, R.R., Pericak-Vance, M.A., Haines, J.L., Erlich, H.A., Hauser, S.L., Oksenberg, J.R. Ann. Neurol. (2004) [Pubmed] • Association of a functional inducible nitric oxide synthase promoter variant with susceptibility to biopsy-proven giant cell arteritis. Gonzalez-Gay, M.A., Oliver, J., Sanchez, E., Garcia-Porrua, C., Paco, L., Lopez-Nevot, M.A., Ollier, W.E., Martin, J. J. Rheumatol. (2005) [Pubmed] • Nitric oxide synthase gene polymorphisms in Alzheimer's disease and dementia with Lewy bodies. Singleton, A.B., Gibson, A.M., McKeith, I.G., Ballard, C.G., Edwardson, J.A., Morris, C.M. Neurosci. Lett. (2001) [Pubmed] • Nitric oxide and macrophage function. MacMicking, J., Xie, Q.W., Nathan, C. Annu. Rev. Immunol. (1997) [Pubmed] • Nitric oxide in health and disease of the respiratory system. Ricciardolo, F.L., Sterk, P.J., Gaston, B., Folkerts, G. Physiol. Rev. (2004) [Pubmed] • Free radicals in the physiological control of cell function. Dröge, W. Physiol. Rev. (2002) [Pubmed] • Bidirectional regulation of osteoclast function by nitric oxide synthase isoforms. Brandi, M.L., Hukkanen, M., Umeda, T., Moradi-Bidhendi, N., Bianchi, S., Gross, S.S., Polak, J.M., MacIntyre, I. Proc. Natl. Acad. Sci. U.S.A. (1995)[Pubmed] • Role of nitric oxide in Sjögren's syndrome. Konttinen, Y.T., Platts, L.A., Tuominen, S., • Regulation of nitric oxide synthesis by proinflammatory cytokines in human umbilical vein endothelial cells. Elevations in tetrahydrobiopterin levels enhance endothelial nitric oxide synthase specific activity. Rosenkranz-Weiss, P., Sessa, W.C., Milstien, S., Kaufman, S., Watson, C.A., Pober, J.S. J. Clin. Invest. (1994) [Pubmed]